| Amber Valene Hawker, PTA | |
|
285 W Francis St, Blackfoot, ID 83221-1751 | |
| (208) 785-0123 | |
| Not Available |
| Full Name | Amber Valene Hawker |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 285 W Francis St, Blackfoot, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053836361 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 5142 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Amber Valene Hawker, PTA 285 W Francis St, Blackfoot, ID 83221-1751 Ph: (208) 785-0123 | Amber Valene Hawker, PTA 285 W Francis St, Blackfoot, ID 83221-1751 Ph: (208) 785-0123 |
News Archive
One impact of health insurance exchanges, proposed by Democrats as part of the health care overhaul, could be better prescription drug coverage for some consumers, the Los Angeles Times explains. The exchanges would require drug coverage as part of a minimum benefits package. The flip side is that some people may be forced to buy drug coverage they don't want.
Researchers from the University of Birmingham and hospitals across the West Midlands have revealed how a common symptomless condition can develop into the blood cancer myeloma.
Amgen (Nasdaq: AMGN) today announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court's decision that Roche's peg-EPO product, Mircera, infringes four Amgen patents ('868, '698, '933 and '422) relating to recombinant erythropoietin (EPO) and processes for making it.
Elsevier, the leading global publisher of scientific, technical, and medical information products and services, announced today it has begun offering Arabic bilingual editions of leading Elsevier medical texts to major universities in the Middle East. The first order was recently received by Kalamoon University in Syria.
A drug already used to treat symptoms of epilepsy has potential to slow the muscle weakening that comes with amyotrophic lateral sclerosis (ALS), scientists report after completing a Phase II clinical trial-an early, small-scale test to show if the drug works and continues to be safe.
› Verified 3 days ago
David J Bilstrom, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 98 Poplar St, Blackfoot, ID 83221 Phone: 208-782-2444 Fax: 208-785-3115 |